One woman died and another is in serious condition after getting the Johnson & Johnson vaccine. Both of them are among the six cases of adverse reaction to the aforementioned jab that led to the decision to halt vaccinations of this product.
This was stated by officials from the U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) who appeared at a press conference on Tuesday after the announcement of a pause in the use of this vaccine.
The suspension that, they recalled, is a recommendation and not a mandate, because, according to the U.S. health authorities, the number of people affected is very small and if a medical professional and his patient understand that the benefit of being vaccinated is greater than the risk and want to go ahead, they can do so.
Physician Peter Marks, head of the FDA’s Center for Biologics Evaluation and Research, explained at the press conference that the six people with adverse effects have suffered a rare type of cerebral thrombosis.
The principal deputy director of the CDC, Anne Schuchat, asked the citizens who have had this vaccine in the last two weeks to monitor the symptoms and go to the doctor if they have severe headaches, abdominal or leg pains, as well as difficulty in breathing.
And he asked medical professionals, when they find patients with low platelet levels, to check whether they have been vaccinated recently.
In any case, Schuchat stressed that those who have been vaccinated with this formula for a longer period of time do not necessarily suffer adverse effects, and added that it is not possible to generalize because the cases recorded represent a very small number.
A number that, in any case, and given the seriousness of the effects suffered, has been sufficient to take the decision to recommend a pause and review all the data.
Marks acknowledged, on the other hand, that the side effects are similar to those reported with the AstraZeneca vaccine.
The CDC has convened a meeting of its advisory committee on immunization practices for Wednesday to further review these cases, and the FDA will also review the analyses.
This bump in the vaccination process need not mean that the goals set by U.S. President Joe Biden – who promised 200 million vaccinated by the time he has been in the White House for 100 days – will be missed, because the vaccine supply, Marks said, is becoming more plentiful.